Benjamin Bender

University Hospital
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Preclinical evidence demonstrates that gut signals influence motivated behavior through the dopaminergic system. However, translational research in humans is scarce, and it is not known if surges of the stomach-derived hormone ghrelin acutely boost motivation via dopamine transmission. To close this gap, we investigated the effects of acyl ghrelin infusions (vs. saline) on instrumental work for rewards, brain responses, and dopamine transmission in healthy adults in a double-blind, randomized and placebo-controlled crossover study with [ 11 C]raclopride PET-fMRI. In line with preclinical findings, ghrelin enhanced hunger sensations ( p = .007), and effort for food and small rewards. Crucially, ghrelin enhanced functional connectivity between the hypothalamus and the striatum (NAcc: p SVC = .016), as well as within the striatum (NAcc<>Putamen: p SVC = .001), pointing to an enhanced coupling between homeostatic and motivational circuits. However, ghrelin did not alter dopamine binding potential (reflecting changes in endogenous tone), but boosted task-free phasic pulses of the NAcc BOLD signal ( p = .020), which were negatively associated with binding potential ( p = .034). During the task, ghrelin increased cue- (precentral gyrus: p FWE = .003) and effort-evoked brain responses (e.g., VTA/SN: p svc = .002) in accordance with increases in motivation. Together, these findings recapitulate preclinical work that ghrelin primarily boosts phasic dopamine release, reflecting enhanced incentive salience of food and smaller rewards. This highlights the potential of targeting gut-brain interactions to improve motivational symptoms, such as loss of appetite or anhedonia. Graphical Abstract

Year:

2025

Objective Spinocerebellar ataxia type 3 (SCA3) is a rare, inherited neurodegenerative disease. Here, we profile the spatial spread of atrophy across the whole brain, determine whether brain degeneration preferentially maps onto specific functional networks, and investigate the relationship between cerebellar and cerebral anatomical changes. Methods Whole-brain grey and white matter (GM and WM) voxel-based morphometry was performed on 408 individuals with SCA3 (82 pre-ataxic) and 293 controls. The SCA3 cohort was stratified by ataxia severity to investigate disease progression, with cerebellar GM atrophy mapped onto a task-based functional atlas. Volume was correlated with disease duration and intensity. Cerebrocerebellar volumetric covariance was assessed to determine whether atrophy was coupled between infra- and supratentorial regions. Results The pattern of atrophy is spatially consistent but progressive in magnitude across the disease course. The greatest atrophy was found in the pons, cerebellar WM, and cerebellar peduncles; correlations with disease severity and duration were also strongest in these regions. Cerebellar GM atrophy was greatest in functional regions associated with motor execution and planning, attention, and emotional processing. Sparse cerebral cortical atrophy appears only in the most severe disease subgroup, while striatal atrophy begins in the earliest stages. Reduced cerebrocerebellar structural covariance is observed in SCA3 participants versus controls. Interpretation While cerebellar and brainstem atrophy become more severe, the pattern of atrophy remains largely consistent as SCA3 progresses. Cerebellar GM degeneration occurs in regions associated with motor, cognitive, and affective control, in line with clinical presentation. Cerebellar atrophy is not directly mirrored by cerebral changes.

Year:

2025

Background/Objectives: This retrospective observational study aimed to investigate the perioperative outcome in Malignant Peripheral Nerve Sheath Tumors (MPNSTs) with and without relation to Neurofibromatosis Type 1 (NF1) and to detect possible influencing factors. Methods: Clinical reports, histopathological evaluations, imaging, and treatment characteristics were reviewed in 35 operated MPNSTs in 33 patients. Possible predictive valuables included disease type, preoperative tumor volume, SUV and MIB-1 proliferation index, resection margins, the presence of metastasis, and whether radio-/chemotherapy was received. Results: Patients with NF1 were younger (mean age: 29 ± 13, 8–54 years) than sporadic cases (mean age: 45 ± 13, 24–67 years) and exhibited significantly larger preoperative tumor volumes (mean 299 vs. 18 cm3, p = 0.048). Most tumors were located in the facial/cervical/neck area (34%, n = 12), followed by the trunk (31%, n = 11), lower extremity (17%, n = 6), upper extremity (14%, n = 5), and intraspinal area (3%, n = 1). NF1-associated MPNSTs appeared predominantly on the trunk (39%) and sporadically in the facial/cervical/neck area (50%). Complete resection was possible in 66% and an improvement in or stability of function was achieved in most cases (motor 69%, sensory 74%), as well as a decrease in pain intensity (63%). NF1-associated MPNSTs exhibited more severe pain scores (median VRS scale 2, p = 0.002) compared to sporadic tumors (median VRS scale 0.5). Sporadic MPNSTs located at the head/facial/brachial plexus and upper extremities exhibited better preoperative functions compared to those on the lower extremities. In 12 cases with available [18F]FDG PET, the mean preoperative SUV (9.8 ± 7.2) positively correlated with the mean maximum MIB-1 index (34 ± 26%, p = 0.005) and the mean preoperative tumor volume (474.7 ± 68.6 cm3, p = 0.047). The overall survival (OS) was significantly longer in tumors with higher resection extents (R0, p = 0.01) and without accompanying metastasis (p = 0.046), and tended to be longer, but not significantly so, in sporadic MPNSTs. In six and seven tumors, with R1/R2 resection margins and present metastasis, respectively, solid or combined neo-/adjuvant radio-/chemotherapy led to a significantly shorter OS (p = 0.014). Conclusions: NF1-associated MPNSTs have larger tumor volumes, higher SUVs and MIB-1 proliferation indices, and a shorter overall survival period. Nevertheless, surgery can improve symptoms, particularly medication-resistant pain, and should also be considered in advanced disease for symptom control/improvement.

Year:

2024

In neuroimaging, there is no equivalent alternative to magnetic resonance imaging (MRI). However, image acquisitions are generally time-consuming, which may limit utilization in some cases, e.g., in patients who cannot remain motionless for long or suffer from claustrophobia, or in the event of extensive waiting times. For multiple sclerosis (MS) patients, MRI plays a major role in drug therapy decision-making. The purpose of this study was to evaluate whether an ultrafast, T2-weighted (T2w), deep learning-enhanced (DL), echo-planar-imaging-based (EPI) fluid-attenuated inversion recovery (FLAIR) sequence (FLAIRUF) that has targeted neurological emergencies so far might even be an option to detect MS lesions of the brain compared to conventional FLAIR sequences. Therefore, 17 MS patients were enrolled prospectively in this exploratory study. Standard MRI protocols and ultrafast acquisitions were conducted at 3 tesla (T), including three-dimensional (3D)-FLAIR, turbo/fast spin-echo (TSE)-FLAIR, and FLAIRUF. Inflammatory lesions were grouped by size and location. Lesion conspicuity and image quality were rated on an ordinal five-point Likert scale, and lesion detection rates were calculated. Statistical analyses were performed to compare results. Altogether, 568 different lesions were found. Data indicated no significant differences in lesion detection (sensitivity and positive predictive value [PPV]) between FLAIRUF and axially reconstructed 3D-FLAIR (lesion size ≥3 mm × ≥2 mm) and no differences in sensitivity between FLAIRUF and TSE-FLAIR (lesion size ≥3 mm total). Lesion conspicuity in FLAIRUF was similar in all brain regions except for superior conspicuity in the occipital lobe and inferior conspicuity in the central brain regions. Further findings include location-dependent limitations of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) as well as artifacts such as spatial distortions in FLAIRUF. In conclusion, FLAIRUF could potentially be an expedient alternative to conventional methods for brain imaging in MS patients since the acquisition can be performed in a fraction of time while maintaining good image quality.

Year:

2024

Magnetic resonance (MR) image acquisitions are usually time-consuming, limiting utilization in neuroimaging. For multiple sclerosis (MS) patients, MR imaging plays a major role in drug therapy decision-making. The purpose of this study was to evaluate whether an ultrafast, T2-weighted (T2w), deep-learning-enhanced (DL), echo-planar-imaging-based (EPI) fluid-attenuated inversion recovery (FLAIR) sequence (FLAIRUF) that has been targeting neurological emergencies so far might even be an option to detect MS lesions of the brain compared to conventional FLAIR sequences. Therefore, 17 MS patients were enrolled prospectively in this exploratory study. Standard MR protocols and ultrafast acquisitions were conducted at 3 tesla (T), including three-dimensional (3D)-FLAIR, turbo/fast spin echo (TSE)-FLAIR, and FLAIRUF. Inflammatory lesions were grouped by size and location. Lesion conspicuity and image quality were rated on an ordinal five-point Likert scale, and lesion detection rates were calculated. Statistical analyses were performed to compare results. Altogether, 568 different lesions were found. Data indicated no significant differences in lesion detection (sensitivity and positive predictive value [PPV]) between FLAIRUF and axially reconstructed 3D-FLAIR (lesion size ≥ 3 mm × ≥ 2 mm) and no differences in sensitivity between FLAIRUF and TSE-FLAIR (lesion size ≥ 3 mm total). Lesion conspicuity in FLAIRUF was similar in all brain regions except for superior conspicuity in the occipital lobe and inferior conspicuity in central brain regions. Further findings include location-dependent limitations of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) as well as artifacts such as spatial distortions in FLAIRUF. In conclusion, FLAIRUF could potentially be an expedient alternative to conventional methods for brain imaging in MS patients since the acquisition can be performed in a fraction of time while maintaining good image quality.

Year:

2024

The 2021 WHO classification of CNS tumors is a challenge for neuroradiologists due to the central role of the molecular profile of tumors. The potential of novel data analysis tools in neuroimaging must be harnessed to maintain its role in predicting tumor subgroups. We performed a scoping review to determine current evidence and research gaps. A comprehensive literature search was conducted regarding glioma subgroups according to the 2021 WHO classification and the use of MRI, radiomics, machine learning, and deep learning algorithms. Sixty-two original articles were included and analyzed by extracting data on the study design and results. Only 8% of the studies included pediatric patients. Low-grade gliomas and diffuse midline gliomas were represented in one-third of the research papers. Public datasets were utilized in 22% of the studies. Conventional imaging sequences prevailed; data on functional MRI (DWI, PWI, CEST, etc.) are underrepresented. Multiparametric MRI yielded the best prediction results. IDH mutation and 1p/19q codeletion status prediction remain in focus with limited data on other molecular subgroups. Reported AUC values range from 0.6 to 0.98. Studies designed to assess generalizability are scarce. Performance is worse for smaller subgroups (e.g., 1p/19q codeleted or IDH1/2 mutated gliomas). More high-quality study designs with diversity in the analyzed population and techniques are needed.

Year:

2024

Objectives Temporal lobe epilepsy (TLE) is commonly associated with mesiotemporal pathology and widespread alterations of grey and white matter structures. Evidence supports a progressive condition although the temporal evolution of TLE is poorly defined. This ENIGMA-Epilepsy study utilized multimodal magnetic resonance imaging (MRI) data to investigate structural alterations in TLE patients across the adult lifespan. We charted both grey and white matter changes and explored the covariance of age-related alterations in both compartments. Methods We studied 769 TLE patients and 885 healthy controls across an age range of 17-73 years, from multiple international sites. To assess potentially non-linear lifespan changes in TLE, we harmonized data and combined median split assessments with cross-sectional sliding window analyses of grey and white matter age-related changes. Covariance analyses examined the coupling of grey and white matter lifespan curves. Results In TLE, age was associated with a robust grey matter thickness/volume decline across a broad cortico-subcortical territory, extending beyond the mesiotemporal disease epicentre. White matter changes were also widespread across multiple tracts with peak effects in temporo-limbic fibers. While changes spanned the adult time window, changes accelerated in cortical thickness, subcortical volume, and fractional anisotropy (all decreased), and mean diffusivity (increased) after age 55 years. Covariance analyses revealed strong limbic associations between white matter tracts and subcortical structures with cortical regions. Conclusions This study highlights the profound impact of TLE on lifespan changes in grey and white matter structures, with an acceleration of aging-related processes in later decades of life. Our findings motivate future longitudinal studies across the lifespan and emphasize the importance of prompt diagnosis as well as intervention in patients.

Year:

2024

In children with bladder/prostate (BP) and perianal rhabdomyosarcoma (RMS), we use a hybrid treatment concept for those suitable, combining organ-preserving tumor resection and high-dose rate brachytherapy (HDR-BT). This treatment concept has been shown to improve outcomes. However, it is associated with specific challenges for the clinicians. The exact position of the tubes for BT is a prerequisite for precise radiotherapy. It can finally be determined only with an MRI or CT scan. We evaluated the use of an intraoperative MRI (iMRI) to control the position of the BT tubes and for radiotherapy planning in all patients with BP and perianal RMS who received the above-mentioned combination therapy in our department since January 2021. iMRI was used in 12 children. All tubes were clearly localized. No adverse events occurred. In all 12 children, radiotherapy could be started on time. In a historical cohort without iMRI, this was not possible in 3 out of 20 children. The use of iMRI in children with BP and perianal RMS improved patient safety and treatment quality. This technology has proven to be successful for the patient population we have defined and has become a standard procedure in our institution.

Year:

2023

Collaborators (59)

Nils Kroemer

Professor of Medical Psychology

University of Bonn

GERMANY
View details

Niels K. Focke

-

GERMANY
View details

Christian Rummel

Professor AI Medical Systems

Deggendorf Institute of Technology

GERMANY
View details

Luis Concha

Professor

National Autonomous University of Mexico

View details

Pasquale Striano

University of Genoa

ITALY
View details

Giulia Coarelli

Institut du Cerveau et de la Moelle Épinière

FRANCE
View details

Ian H. Harding

Group Leader

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Antonio Gambardella

Professor of Neurology

Università degli Studi Mediterranea di Reggio Calabria

ITALY
View details

Mariasavina Severino

IRCCS Istituto Giannina Gaslini

ITALY
View details

Terence O'Brien

MONASH UNIVERSITY

AUSTRALIA
View details

Julie Absil

Hôpital Erasme

BELGIUM
View details

Thiago Rezende

Associate Researcher

University of Campinas

BRAZIL
View details

John S Duncan

University College London

UNITED KINGDOM
View details

Theodor Rüber

University Hospital Bonn

GERMANY
View details

Lorenzo Caciagli

PI

University of Pennsylvania

UNITED STATES
View details

Chiadi Onyike

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Ezequiel Gleichgerrcht

Assistant Professor

Emory University

UNITED STATES
View details

Orrin Devinsky

Professor of Neurosurgery, Psychiatry, and Neurology

NYU School of Medicine

UNITED STATES
View details

Mark Philip Richardson

King’s College London

UNITED KINGDOM
View details

Gerald Reischl

Head of Radiopharmacy

University Hospital of Tuebingen

GERMANY
View details

Andreas Deistung

University Hospital Halle (Saale)

GERMANY
View details

Sara Larivière

Assistant Professor

Université de Sherbrooke

CANADA
View details

Kathrin Reetz

Full Professor for Translational Neurodegeneration

-

GERMANY
View details

Gianpiero Cavalleri

Professor of Human Genetics

-

IRELAND
View details

Heath Pardoe

Associate Professor

MONASH UNIVERSITY

AUSTRALIA
View details

Sabine Ellinger

Professor

University of Bonn

GERMANY
View details

Patricia Desmond

head

University of Melbourne

AUSTRALIA
View details

Sanjay Sisodiya

University College London

UNITED KINGDOM
View details

Peter Taylor

UKRI Future Leaders Fellow / Professor

Newcastle University

UNITED KINGDOM
View details

Maria Eugenia Caligiuri

Professore Associato

-

ITALY
View details

Leonardo Bonilha

University of South Carolina

UNITED STATES
View details

Simon Keller

Chair

University of Liverpool

UNITED KINGDOM
View details

Rhys Thomas

Reader in Epilepsy

Newcastle University Faculty of Medical Sciences

UNITED KINGDOM
View details

Patrick Kwan

-

AUSTRALIA
View details

Fernando Cendes

Full Professor

University of Campinas

BRAZIL
View details

Lucy Vivash

MONASH UNIVERSITY

AUSTRALIA
View details

Edward Boyd

Assistant Professor-Research

Michigan State University

UNITED STATES
View details

Martin Walter

Professor

Eberhard Karls Universität Tübingen

GERMANY
View details

Colin Doherty

Prof.

Trinity College Dublin

IRELAND
View details

Matthis Synofzik

Professor

Hertie Institute for clinical brain research

GERMANY
View details

Stefano Meletti

Direttore

-

ITALY
View details

Alexandra Durr

Professor, MD, PhD

Sorbonne Université

FRANCE
View details

Gavin Winston

Professor of Neurology

Queen's University

CANADA
View details

Bart van de Warrenburg

Associate professor, neurologist, principal investigator

Radboud Universitair Medisch Centrum

NETHERLANDS
View details

David Arpin

University of Florida

UNITED STATES
View details

Dewi Schrader

Clinical Assistant Professor, Paediatric Neurologist

-

CANADA
View details

Clarissa Yasuda

Associate Professor

University of Campinas

BRAZIL
View details

Martin Domin

Senior researcher

University Medicine Greifswald

GERMANY
View details

Boris C. Bernhardt

Associate Professor

McGill University

CANADA
View details

Anna Elisabetta Vaudano

University of Modena and Reggio Emilia

ITALY
View details

Angelo Labate

Full Professor of Neurology

University of Messina

ITALY
View details

Renzo Guerrini

AOU Meyer

ITALY
View details

Dagmar Timmann

University Hospital Essen

GERMANY
View details

Jennifer Faber

Head of Ataxia Clinic

University Hospital Bonn

GERMANY
View details

Marian Galovic

Head of Epilepsy Unit, Consultant Neurologist

University of Zurich

SWITZERLAND
View details

Marcondes França Junior

Assistant professor

University of Campinas

BRAZIL
View details

Jerry L. Prince

William B Kouwenhoven Professor

Johns Hopkins University

UNITED STATES
View details

Gulin Oz

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Henry Paulson

University of Michigan

UNITED STATES
View details